GHDX Share Price

Open 28.46 Change Price %
High 29.26 1 Day 0.61 2.14
Low 28.45 1 Week 0.88 3.12
Close 29.11 1 Month 1.53 5.55
Volume 158076 1 Year 2.64 9.97
52 Week High 33.96
52 Week Low 22.00
GHDX Important Levels
Resistance 2 29.86
Resistance 1 29.55
Pivot 28.94
Support 1 28.67
Support 2 28.36
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
CSCO 33.74 0.42%
CSCO 33.74 0.42%
More..
NASDAQ USA Top Gainers Stocks
MOSY 3.50 54.19%
LOCM 0.09 50.00%
LMIA 13.66 48.64%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
IFON 0.75 25.00%
PPHM 0.55 25.00%
GSIT 6.99 22.20%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Genomic Health, Inc. (NASDAQ: GHDX)

GHDX Technical Analysis 1.5
As on 17th Feb 2017 GHDX Share Price closed @ 29.11 and we RECOMMEND Buy for LONG-TERM with Stoploss of 28.09 & Sell for SHORT-TERM with Stoploss of 29.12 we also expect STOCK to react on Following IMPORTANT LEVELS.
GHDX Target for February
1st Target up-side 29.41
2nd Target up-side 30.76
3rd Target up-side 32.11
1st Target down-side 25.55
2nd Target down-side 24.2
3rd Target down-side 22.85
GHDX Other Details
Segment EQ
Market Capital 993752640.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.genomichealth.com
GHDX Address
GHDX
301 Penobscot Drive
Redwood City, CA 94063
United States
Phone: 650-556-9300
GHDX Latest News
Interactive Technical Analysis Chart Genomic Health, Inc. ( GHDX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Genomic Health, Inc.
GHDX Business Profile
Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.